<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04107129</url>
  </required_header>
  <id_info>
    <org_study_id>51702</org_study_id>
    <nct_id>NCT04107129</nct_id>
  </id_info>
  <brief_title>Predicting Endometrial Receptivity for Optimal Reproductive Management</brief_title>
  <acronym>PERFORM</acronym>
  <official_title>Predicting Endometrial Receptivity for Optimal Reproductive Management (PERFORM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand why some women are infertile (unable to conceive a
      child). The investigators hope to learn if an endometrial biopsy after egg retrieval is
      feasible for detecting biomarkers for endometriosis and predicting implantation and pregnancy
      rate after embryo transfer.

      This study design will provide for the first time, an opportunity to compare endometrial
      biopsy material from hyperstimulated (gonadotropin treated) subjects after egg retrieval. If
      successful, it would provide a new protocol for women with unexplained infertility or those
      with known endometriosis to avoid poor IVF outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will recruit 100 women who are undergoing IVF with egg retrieval and
      delayed embryo transfer to consent to endometrial biopsy 1 week after egg retrieval.
      Currently most women in the Stanford's IVF program undergo egg retrieval with delayed embryo
      transfer (ET) with preimplantation genetic testing of embryos. This delay allows most to
      avoid the condition known as ovarian hyperstimulation and allows time for genetic screening
      (PGT-A) performed on embryos. Such a delay also opens the window for endometrial assessment
      for proteins like SIRT1 and BCL6 that have been suggested to be associated with
      endometriosis. Endometriosis is thought to cause IVF failure (Littman et al., 2002); by
      treating endometriosis in the future, clinicians might avoid IVF failure due to an unexpected
      non-receptive endometrium (Littman et al., 2002). This study design will provide for the
      first time, an opportunity to compare endometrial biopsy material from hyperstimulated
      (gonadotropin treated) subjects after egg retrieval. If successful, it would provide a new
      protocol for women with unexplained infertility or those with known endometriosis to avoid
      poor IVF outcomes.

      There is some evidence that endometrial scratching (biopsy) may enhance embryo attachment in
      future cycles (Vitagliano et al., 2018), although not all studies agree (Lensen et al.,
      2019). The endometrial biopsy taken in the secretory phase will be tested for BCL6 and SIRT1
      expression, two proteins highly associated with the presence of endometriosis (Yoo et al.,
      2017). The samples of endometrium will be processed (put into formalin and paraffin blocks or
      saved in RNA later and not be analyzed until after completion of the ART cycle. Patients as
      well as the clinicians will be blinded to results and until the conclusion of the ART cycle
      following embryo transfer and subsequent pregnancy testing. This will be done to avoid
      interfering with the current ART cycle and to avoid the introduction of bias. Patients will
      be provided with test results after completion of the first embryo transfer if they wish to
      know.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SIRT1 gene expression in the endometrium</measure>
    <time_frame>2-3 years</time_frame>
    <description>Endometrial biopsy specimens will be stained for SIRT1 using immunostaining and Hscore assignment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BCL6 expression in the endometrium</measure>
    <time_frame>2-3 years</time_frame>
    <description>Endometrial biopsy specimens will be stained for BCL6 using immunostaining and Hscore assignment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who have a positive pregnancy test (HCG level &gt; 5) 9 days after embryo transfer</measure>
    <time_frame>2-3 years</time_frame>
    <description>pregnancy rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of embryo transfers that lead to live births</measure>
    <time_frame>2-3 years</time_frame>
    <description>live birth rate</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Infertility, Female</condition>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Known Endometriosis</arm_group_label>
    <description>Known Endometriosis undergoing IVF with PGTA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unexplained Infertility</arm_group_label>
    <description>Unexplained Infertility undergoing IVF with PGTA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Risk Controls</arm_group_label>
    <description>Low Risk Controls undergoing IVF with PGTA</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endometrial Biopsy</intervention_name>
    <description>An endometrial biopsy is the removal of a small piece of tissue from the endometrium, which is the lining of the uterus. Endometrial tissue will be tested for BCL6 and SIRT1 Biomarkers</description>
    <arm_group_label>Known Endometriosis</arm_group_label>
    <arm_group_label>Low Risk Controls</arm_group_label>
    <arm_group_label>Unexplained Infertility</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Euploid embryo transfer</intervention_name>
    <description>Patients undergoing IVF and Preimplantation genetic testing will undergo delayed euploid frozen embryo transfer per clinical protocol and standard of care.</description>
    <arm_group_label>Known Endometriosis</arm_group_label>
    <arm_group_label>Low Risk Controls</arm_group_label>
    <arm_group_label>Unexplained Infertility</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Estradiol and Progesterone levels in the blood will be checked</description>
    <arm_group_label>Known Endometriosis</arm_group_label>
    <arm_group_label>Low Risk Controls</arm_group_label>
    <arm_group_label>Unexplained Infertility</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Endometrial biopsy will be collected. Urine, saliva, and blood samples will also be collected
      for future studies
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        These criteria are meant to define two populations of women (high and low risk for
        endometriosis) and not include confounding diagnoses including PCOS, autoimmune conditions
        and endocrine disorders such as hypothyroidism and hyperprolactinemia.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age - 18 to 42

          2. AMH â‰¥ 1

          3. Planning to undergo IVF with delayed embryo transfer

          4. Must have blastocyst(s) by day 6 that were biopsied for PGT-A

          5. BMI 18-35

        Exclusion Criteria:

          1. Uterine fibroids &gt; 4 cm in size

          2. Polycystic ovary syndrome (PCOS) according with the Rotterdam criteria.

          3. Ovarian failure and subjects receiving donor oocytes/embryos

          4. Anti-cardiolipid and/or lupus anti-coagulant abnormalities by history

          5. Diabetes mellitus (Type I or Type II)

          6. Untreated hypothyroidism

          7. Hyperprolactinemia

          8. Uncorrected uterine anomaly
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Adult females of reproductive age.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruth B Lathi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Fertility and Reproductive Health</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94087</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study team</last_name>
      <phone>408-688-9892</phone>
      <email>reiresearch@lists.stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Budwit-Novotny DA, McCarty KS, Cox EB, Soper JT, Mutch DG, Creasman WT, Flowers JL, McCarty KS Jr. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res. 1986 Oct;46(10):5419-25.</citation>
    <PMID>3756890</PMID>
  </reference>
  <reference>
    <citation>Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, Brodszky V, Canis M, Colombo GL, DeLeire T, Falcone T, Graham B, Halis G, Horne A, Kanj O, Kjer JJ, Kristensen J, Lebovic D, Mueller M, Vigano P, Wullschleger M, D'Hooghe T. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod. 2012 May;27(5):1292-9. doi: 10.1093/humrep/des073. Epub 2012 Mar 14. Erratum in: Hum Reprod. 2014 Sep;29(9):2073.</citation>
    <PMID>22422778</PMID>
  </reference>
  <reference>
    <citation>Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012 Sep;98(3):511-9. doi: 10.1016/j.fertnstert.2012.06.029. Epub 2012 Jul 20. Review.</citation>
    <PMID>22819144</PMID>
  </reference>
  <reference>
    <citation>Endometriosis exerts &quot;profound&quot; economic burden in the US. (2007). PharmacoEconomics &amp; Outcomes News. https://doi.org/10.2165/00151234-200705230-00025</citation>
  </reference>
  <reference>
    <citation>Evans-Hoeker E, Lessey BA, Jeong JW, Savaris RF, Palomino WA, Yuan L, Schammel DP, Young SL. Endometrial BCL6 Overexpression in Eutopic Endometrium of Women With Endometriosis. Reprod Sci. 2016 Sep;23(9):1234-41. doi: 10.1177/1933719116649711. Epub 2016 May 24.</citation>
    <PMID>27222232</PMID>
  </reference>
  <reference>
    <citation>Fox C, Morin S, Jeong JW, Scott RT Jr, Lessey BA. Local and systemic factors and implantation: what is the evidence? Fertil Steril. 2016 Apr;105(4):873-84. doi: 10.1016/j.fertnstert.2016.02.018. Epub 2016 Mar 3. Review.</citation>
    <PMID>26945096</PMID>
  </reference>
  <reference>
    <citation>Lensen S, Osavlyuk D, Armstrong S, Stadelmann C, Hennes A, Napier E, Wilkinson J, Sadler L, Gupta D, Strandell A, Bergh C, Vigneswaran K, Teh WT, Hamoda H, Webber L, Wakeman SA, Searle L, Bhide P, McDowell S, Peeraer K, Khalaf Y, Farquhar C. A Randomized Trial of Endometrial Scratching before In Vitro Fertilization. N Engl J Med. 2019 Jan 24;380(4):325-334. doi: 10.1056/NEJMoa1808737.</citation>
    <PMID>30673547</PMID>
  </reference>
  <reference>
    <citation>Lessey BA, Metzger DA, Haney AF, McCarty KS Jr. Immunohistochemical analysis of estrogen and progesterone receptors in endometriosis: comparison with normal endometrium during the menstrual cycle and the effect of medical therapy. Fertil Steril. 1989 Mar;51(3):409-15.</citation>
    <PMID>2646155</PMID>
  </reference>
  <reference>
    <citation>Lessey BA, Palomino WA, Apparao KB, Young SL, Lininger RA. Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women. Reprod Biol Endocrinol. 2006;4 Suppl 1:S9.</citation>
    <PMID>17118173</PMID>
  </reference>
  <reference>
    <citation>Likes CE, Cooper LJ, Efird J, Forstein DA, Miller PB, Savaris R, Lessey BA. Medical or surgical treatment before embryo transfer improves outcomes in women with abnormal endometrial BCL6 expression. J Assist Reprod Genet. 2019 Mar;36(3):483-490. doi: 10.1007/s10815-018-1388-x. Epub 2019 Jan 4.</citation>
    <PMID>30610661</PMID>
  </reference>
  <reference>
    <citation>Littman E, Giudice L, Lathi R, Berker B, Milki A, Nezhat C. Role of laparoscopic treatment of endometriosis in patients with failed in vitro fertilization cycles. Fertil Steril. 2005 Dec;84(6):1574-8.</citation>
    <PMID>16359945</PMID>
  </reference>
  <reference>
    <citation>Meyer WR, Lessey BA, Castelbaum AJ. Hydrosalpinx and altered uterine receptivity. Fertil Steril. 1997 Nov;68(5):944-5.</citation>
    <PMID>9389833</PMID>
  </reference>
  <reference>
    <citation>Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998 Apr 30;17(8):857-72.</citation>
    <PMID>9595616</PMID>
  </reference>
  <reference>
    <citation>Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril. 1997 May;67(5):817-21.</citation>
    <PMID>9130884</PMID>
  </reference>
  <reference>
    <citation>Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101-8.</citation>
    <PMID>18546601</PMID>
  </reference>
  <reference>
    <citation>Talbi S, Hamilton AE, Vo KC, Tulac S, Overgaard MT, Dosiou C, Le Shay N, Nezhat CN, Kempson R, Lessey BA, Nayak NR, Giudice LC. Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women. Endocrinology. 2006 Mar;147(3):1097-121. Epub 2005 Nov 23.</citation>
    <PMID>16306079</PMID>
  </reference>
  <reference>
    <citation>Vitagliano A, Di Spiezio Sardo A, Saccone G, Valenti G, Sapia F, Kamath MS, Blaganje M, Andrisani A, Ambrosini G. Endometrial scratch injury for women with one or more previous failed embryo transfers: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2018 Sep;110(4):687-702.e2. doi: 10.1016/j.fertnstert.2018.04.040.</citation>
    <PMID>30196966</PMID>
  </reference>
  <reference>
    <citation>Yoo JY, Kim TH, Fazleabas AT, Palomino WA, Ahn SH, Tayade C, Schammel DP, Young SL, Jeong JW, Lessey BA. KRAS Activation and over-expression of SIRT1/BCL6 Contributes to the Pathogenesis of Endometriosis and Progesterone Resistance. Sci Rep. 2017 Jul 28;7(1):6765. doi: 10.1038/s41598-017-04577-w.</citation>
    <PMID>28754906</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 17, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Ruth Bunker Lathi</investigator_full_name>
    <investigator_title>Professor, Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <keyword>Infertility</keyword>
  <keyword>Endometriosis</keyword>
  <keyword>BLC6</keyword>
  <keyword>SIRT1</keyword>
  <keyword>In Vitro Fertilization (IVF)</keyword>
  <keyword>Embryo Transfer (ET)</keyword>
  <keyword>Frozen Embryo Transfer (FET)</keyword>
  <keyword>Assisted Reproductive Technology (ART)</keyword>
  <keyword>PERFORM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No PHI will be shared with collaborators. Collaborators will only have access to aggregate data by study group</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

